Global Markets for Emerging Insulin Drug and Delivery Technologies: Focus on Syringes and Vials

Global Markets for Emerging Insulin Drug and Delivery Technologies: Focus on Syringes and Vials

Report Scope:

This report discusses the implications of the growing diabetes epidemic on the global and regional markets for emerging insulin drug and delivery technologies. It discusses companies in the relevant pharmaceutical and medical industries and provides profiles of the leading players as well as an update on M&A activity. The report’s patent analysis focuses on developments in Japan, Europe and the U.S. Five-year global sales forecasts are provided for the major categories of insulin drug and delivery technologies and devices categories.

This report segments the global market into four regions

North America.

Europe.

Asia-Pacific.

Rest of the World (RoW).

Report Includes:

57 data tables and 83 additional tables

An overview and industry analysis of the global markets for emerging insulin drug and delivery technologies, with an emphasis on plastic insulin syringes and vials

Analyses of the global market trends, with historical market revenue data (sales figures) for 2020 to 2022, estimates for 2023, and projections of compound annual growth rates (CAGRs) through 2028

Estimate of the actual market size and revenue growth forecast, and a corresponding market share analysis by product type, application and region

A look at the emerging technologies that have potential in the diabetes market, with improved glucose control, along with improved delivery methods

Examination of the current state of the insulin drug and delivery industry structure, focusing on technological updates and issues surrounding insulin pens and insulin syringes, ongoing research activities, and regulatory and pricing scenarios

Discussion of market dynamics, clinical trial applications, regulations, and penetration of technologies in the pharmaceutical and biotechnology markets

Discussion of the ESG developments and how they impact corporate performance, ratings and matrices and consumer attitude, as well as the ESG practices of leading pharma and biotech companies

Review of the key patent grants/publications for insulin as a drug, along with its delivery methods

Analysis of the competitive landscape based on recent developments and segmental revenues of leading companies

Profiles of the leading market players